eClinical Technology and Industy News

Inovio stock surges after experimental Covid-19 vaccine shows long-term protection in animals

Excerpt from the article:

“Inovio’s stock climbed as much as 15% in pre-market trading Thursday after the Montgomery County biopharmaceutical company announced its Covid-19 vaccine candidate was effective in protecting non-human primates from the virus 13 weeks after the last vaccination.

The stock was up more than 6% to $20.73 per share at Thursday’s close.

According to the company, its experimental DNA-based vaccine, INO-4800, showed durable antibody and T cell responses in rhesus macaques, a monkey species, for four months.”

Click the button below to read the Article:

Continue Reading The Article

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives